Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Pfizer and Innovent Biologics have entered a global strategic collaboration to develop 12 early-stage oncology programs, including antibody-drug conjugates and multi-specific antibodies. Innovent will receive a $650 million upfront payment and up to $9.85 billion in milestones, bringing the total deal value to $10.5 billion. Innovent retains Greater China rights for four co-developed programs.
Key figures
- Deal Value Usd
- 10500000000
- Programs count
- 12
- Upfront payment
- 650000000
- Milestone payments
- 9850000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.